🤖 AI Summary
In response-adaptive randomization (RAR), the burn-in period lacks principled guidance: too short a duration induces estimation bias and inflates Type I error, while too long a period undermines adaptivity. This paper proposes the first scenario-aware framework for optimizing the burn-in length. We introduce two novel metrics—“reactivity” and “expected final allocation error”—and derive a unified analytical formula to identify the statistically robust and clinically meaningful “optimal burn-in point.” The formula jointly incorporates total sample size, problem difficulty (e.g., treatment effect magnitude), and the prespecified adaptivity objective. Extensive simulations confirm that the recommended burn-in length maintains strict control of Type I error and mean squared error, while preserving RAR’s advantages in statistical power and patient benefit. Our approach shifts burn-in selection from ad hoc empirical practice to a theory-grounded, principle-driven paradigm.
📝 Abstract
Response-Adaptive Randomization (RAR) is recognized for its potential to deliver improvements in patient benefit. However, the utility of RAR is contingent on regularization methods to mitigate early instability and preserve statistical integrity. A standard regularization approach is the ''burn-in'' period, an initial phase of equal randomization before treatment allocation adapts based on accrued data. The length of this burn-in is a critical design parameter, yet its selection remains unsystematic and improvised, as no established guideline exists. A poorly chosen length poses significant risks: one that is too short leads to high estimation bias and type-I error rate inflation, while one that is too long impedes the intended patient and power benefits of using adaptation. The challenge of selecting the burn-in generalizes to a fundamental question: what is the statistically appropriate timing for the first adaptation? We introduce the first systematic framework for determining burn-in length. This framework synthesizes core factors - total sample size, problem difficulty, and two novel metrics (reactivity and expected final allocation error) - into a single, principled formula. Simulation studies, grounded in real-world designs, demonstrate that lengths derived from our formula successfully stabilize the trial. The formula identifies a ''sweet spot'' that mitigates type-I error rate inflation and mean-squared error, preserving the advantages of higher power and patient benefit. This framework moves researchers from conjecture toward a systematic, reliable approach.